Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer.
Cytotoxic activity of NK cells was estimated as related to IL-10 and TGF-beta1 serum levels and Helicobacter pylori infection in gastric cancer patients. Moreover, we sought to determine whether human gastric adenocarcinoma cells in vitro release IL-10, TGF-beta1 or factor(s) affecting NK cytotoxicity. The studies were conducted on 42 patients with gastric cancer (14 with I-II stage-group 1; 28 with III-IV stage-group 2) and on 20 healthy volunteers. The cytotoxicity was tested on NK cells isolated from peripheral blood. IL-10 and TGF-beta1 levels were determined by ELISA. H. pylori was detected in cultures of gastric mucosa biopsies and in direct preparations. In 71.4% patients of group 1 NK cytotoxicity and IL-10 serum levels remained within a normal range while in 68% patients of group 2 a marked decrease was noted in cytotoxic function of NK cells, accompanied by increased levels of IL-10 in serum. In turn, in most patients of either group, independently of NK cytotoxicity and stage grouping in the patients, elevated serum levels of TGF-beta1 were detected. Presence of H. pylori infection manifested no relationship with NK cytotoxicity, IL-10, or the TGF-beta1 serum levels. In cultures of tumour cells presence of IL-10 and TGF-beta1 was demonstrated. Nevertheless, supernatants of the cultures did not change cytotoxic activity of NK cells. Development of gastric carcinoma is accompanied by markedly decreased cytotoxic function of NK cells and by elevated IL-10 and TGF-beta1 serum levels. Gastric carcinoma cells may release IL-10, the suppressive activity of which may in a secondary manner decrease NK cytotoxicity.
Szkaradkiewicz
Andrzej
A
Department of Medical Microbiology, University of Medical Sciences in Poznań, Wieniawskiego 3 Street, 61-712 Poznań, Poland.
Karpiński
Tomasz M
TM
Drews
Michał
M
Borejsza-Wysocki
Maciej
M
Majewski
Przemysław
P
Andrzejewska
Ewa
E
D000368:Aged; D016022:Case-Control Studies; D003602:Cytotoxicity, Immunologic; D005260:Female; D016481:Helicobacter Infections / Q000097:blood / Q000276:immunology; D016480:Helicobacter pylori; D006801:Humans; D016753:Interleukin-10 / Q000097:blood / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D013274:Stomach Neoplasms / Q000097:blood / Q000276:immunology*; D053773:Transforming Growth Factor beta1 / Q000097:blood / Q000276:immunology*; D014407:Tumor Cells, Cultured
C508609:IL10 protein, human; D053773:Transforming Growth Factor beta1; D016753:Interleukin-10
Cancer Lett. 1996 Jun 24;104(1):1-5
8640735
Med Sci Monit. 2003 Jul;9(7):SR53-66
12883469
In Vivo. 1994 May-Jun;8(3):279-83
7803704
Cancer. 1999 Nov 15;86(10):1936-43
10570416
J Exp Med. 1991 Apr 1;173(4):869-79
1672545
J Gastroenterol Hepatol. 2001 Feb;16(2):142-8
11207893
J Surg Res. 2007 May 15;139(2):182-8
17270215
Curr Opin Immunol. 2001 Apr;13(2):154-62
11228407
Nat Rev Immunol. 2003 May;3(5):413-25
12766763
Clin Cancer Res. 1995 Jan;1(1):129-36
9815895
Infect Immun. 2005 Mar;73(3):1482-90
15731046
Eur J Immunol. 1999 Sep;29(9):2658-65
10508240
Am J Gastroenterol. 2001 Feb;96(2):574-8
11232710
Annu Rev Immunol. 1998;16:137-61
9597127
Eur J Cancer. 2006 Apr;42(6):708-16
16556496
Curr Opin Immunol. 2005 Apr;17(2):151-8
15766674
Br J Cancer. 1998 Nov;78(10):1373-8
9823982
Genes Immun. 2004 Dec;5(8):621-30
15573087
Lancet Infect Dis. 2006 Sep;6(9):557-69
16931407
Trends Immunol. 2001 Nov;22(11):633-40
11698225
Genes Dev. 1994 Jan;8(2):133-46
8299934
Cytokine. 2005 Feb 21;29(4):141-52
15652446
J Immunol. 2004 Jul 15;173(2):1249-57
15240717
Annu Rev Immunol. 2001;19:683-765
11244051
Zhonghua Zhong Liu Za Zhi. 1994 Jul;16(4):299-301
7805562
Eur J Immunol. 2001 Oct;31(10):3121-7
11592089
Immunology. 2006 Apr;117(4):433-42
16556256
World J Gastroenterol. 2006 Jul 28;12(28):4473-7
16874857
Gastroenterology. 2003 May;124(5):1193-201
12730860
Stem Cells. 1997;15(3):190-7
9170210